Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy
The objective of this study was to identify prognostic factors for survival in patients with advanced oesophageal cancer, who are treated with cisplatin-based combination chemotherapy. We analysed the baseline characteristics of 350 patients who were treated in six consecutive prospective trials wit...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2003-12, Vol.89 (11), p.2045-2050 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2050 |
|---|---|
| container_issue | 11 |
| container_start_page | 2045 |
| container_title | British journal of cancer |
| container_volume | 89 |
| creator | Polee, M B Hop, W C J Kok, T C Eskens, F A L M van der Burg, M E L Splinter, T A W Siersema, P D Tilanus, H W Stoter, G van der Gaast, A |
| description | The objective of this study was to identify prognostic factors for survival in patients with advanced oesophageal cancer, who are treated with cisplatin-based combination chemotherapy. We analysed the baseline characteristics of 350 patients who were treated in six consecutive prospective trials with one of the following regimens: cisplatin/etoposide, cisplatin/etoposide/5-fluorouracil, cisplatin/paclitaxel (weekly) and cisplatin/paclitaxel (biweekly). Predictive factors in univariate analyses were further evaluated using multivariate analysis (Cox regression). The median survival of all patients was 9 months. The 1, 2 and 5-year survival rates were 33, 12 and 4%, respectively. The main prognostic factors were found to be WHO performance status (0 or 1
vs
2), lactate dehydrogenase (normal
vs
elevated), extent of disease (limited disease defined as locoregional irresectable disease or lymph node metastases confined to either the supraclavicular or celiac region
vs
extensively disseminated disease) in addition to the type of treatment (weekly or biweekly cisplatin/paclitaxel regimen
vs
4-weekly cisplatin/etoposide with or without 5-fluorouracil). Although weight loss, liver metastases and alkaline phosphatase were significant prognostic factors in univariate analyses, these factors lost their significance in multivariate analyses. The median survival for patients without any risk factors was 12 months, compared to only 4 months in patients with WHO 2 plus elevated LDH and extensive disease. The performance status, extent of disease, LDH and the addition of paclitaxel to cisplatin are independent prognostic factors in patients with advanced oesophageal cancer, who are treated with cisplatin-based combination chemotherapy. |
| doi_str_mv | 10.1038/sj.bjc.6601364 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2376851</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71421665</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-e37c399e89e70ed95210c86bba7b1f7984e78e5e221d59c21d51d478a0da399b3</originalsourceid><addsrcrecordid>eNp1kc-L1DAUx4Mo7rh69ShBcG-dzY-2SS_CsrgqLOhBzyFNX6cpnaQm6che_cvNOMVRwRwS8t7n-80LX4ReUrKlhMvrOG7b0WzrmlBel4_QhlacFVQy8RhtCCGiIA0jF-hZjGO-NkSKp-iClnUpsmCDfnwOfud8TNbgXpvkQ8S9Dzgu4WAPesLW4VknCy5F_N2mAevuoJ2BDnuIfh70DjJljqWAUwCdcusXaGycpyx1RatjLhq_b63LBe-wGWDv0wBBzw_P0ZNeTxFerOcl-nr37svth-L-0_uPtzf3hSklTwVwYXjTgGxAEOiailFiZN22WrS0F40sQUiogDHaVY057rQrhdSk01nX8kv09uQ7L-0eOpO_FPSk5mD3Ojwor636u-PsoHb-oBgXtaxoNrhaDYL_tkBMam-jgWnSDvwSlaAlo3VdZfD1P-Dol-Dy5xRjTV6k4RnaniATfIwB-t-TUKKO2ao4qpytWrPNgld_zn_G1zAz8GYFdDR66kMOxcYzV3HOa3k0uj5xMbfcDsJ5vP88_RPcscFn</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229999093</pqid></control><display><type>article</type><title>Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Polee, M B ; Hop, W C J ; Kok, T C ; Eskens, F A L M ; van der Burg, M E L ; Splinter, T A W ; Siersema, P D ; Tilanus, H W ; Stoter, G ; van der Gaast, A</creator><creatorcontrib>Polee, M B ; Hop, W C J ; Kok, T C ; Eskens, F A L M ; van der Burg, M E L ; Splinter, T A W ; Siersema, P D ; Tilanus, H W ; Stoter, G ; van der Gaast, A</creatorcontrib><description>The objective of this study was to identify prognostic factors for survival in patients with advanced oesophageal cancer, who are treated with cisplatin-based combination chemotherapy. We analysed the baseline characteristics of 350 patients who were treated in six consecutive prospective trials with one of the following regimens: cisplatin/etoposide, cisplatin/etoposide/5-fluorouracil, cisplatin/paclitaxel (weekly) and cisplatin/paclitaxel (biweekly). Predictive factors in univariate analyses were further evaluated using multivariate analysis (Cox regression). The median survival of all patients was 9 months. The 1, 2 and 5-year survival rates were 33, 12 and 4%, respectively. The main prognostic factors were found to be WHO performance status (0 or 1
vs
2), lactate dehydrogenase (normal
vs
elevated), extent of disease (limited disease defined as locoregional irresectable disease or lymph node metastases confined to either the supraclavicular or celiac region
vs
extensively disseminated disease) in addition to the type of treatment (weekly or biweekly cisplatin/paclitaxel regimen
vs
4-weekly cisplatin/etoposide with or without 5-fluorouracil). Although weight loss, liver metastases and alkaline phosphatase were significant prognostic factors in univariate analyses, these factors lost their significance in multivariate analyses. The median survival for patients without any risk factors was 12 months, compared to only 4 months in patients with WHO 2 plus elevated LDH and extensive disease. The performance status, extent of disease, LDH and the addition of paclitaxel to cisplatin are independent prognostic factors in patients with advanced oesophageal cancer, who are treated with cisplatin-based combination chemotherapy.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6601364</identifier><identifier>PMID: 14647136</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - mortality ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - mortality ; Cisplatin - administration & dosage ; Cisplatin - therapeutic use ; Clinical ; Drug Resistance ; Epidemiology ; Esophageal Neoplasms - drug therapy ; Esophageal Neoplasms - mortality ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Molecular Medicine ; Multivariate Analysis ; Oncology ; Prognosis ; Tumors</subject><ispartof>British journal of cancer, 2003-12, Vol.89 (11), p.2045-2050</ispartof><rights>The Author(s) 2003</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Dec 1, 2003</rights><rights>Copyright © 2003 Cancer Research UK 2003 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-e37c399e89e70ed95210c86bba7b1f7984e78e5e221d59c21d51d478a0da399b3</citedby><cites>FETCH-LOGICAL-c483t-e37c399e89e70ed95210c86bba7b1f7984e78e5e221d59c21d51d478a0da399b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376851/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376851/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,309,310,314,723,776,780,785,786,881,23909,23910,25118,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15333684$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14647136$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Polee, M B</creatorcontrib><creatorcontrib>Hop, W C J</creatorcontrib><creatorcontrib>Kok, T C</creatorcontrib><creatorcontrib>Eskens, F A L M</creatorcontrib><creatorcontrib>van der Burg, M E L</creatorcontrib><creatorcontrib>Splinter, T A W</creatorcontrib><creatorcontrib>Siersema, P D</creatorcontrib><creatorcontrib>Tilanus, H W</creatorcontrib><creatorcontrib>Stoter, G</creatorcontrib><creatorcontrib>van der Gaast, A</creatorcontrib><title>Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>The objective of this study was to identify prognostic factors for survival in patients with advanced oesophageal cancer, who are treated with cisplatin-based combination chemotherapy. We analysed the baseline characteristics of 350 patients who were treated in six consecutive prospective trials with one of the following regimens: cisplatin/etoposide, cisplatin/etoposide/5-fluorouracil, cisplatin/paclitaxel (weekly) and cisplatin/paclitaxel (biweekly). Predictive factors in univariate analyses were further evaluated using multivariate analysis (Cox regression). The median survival of all patients was 9 months. The 1, 2 and 5-year survival rates were 33, 12 and 4%, respectively. The main prognostic factors were found to be WHO performance status (0 or 1
vs
2), lactate dehydrogenase (normal
vs
elevated), extent of disease (limited disease defined as locoregional irresectable disease or lymph node metastases confined to either the supraclavicular or celiac region
vs
extensively disseminated disease) in addition to the type of treatment (weekly or biweekly cisplatin/paclitaxel regimen
vs
4-weekly cisplatin/etoposide with or without 5-fluorouracil). Although weight loss, liver metastases and alkaline phosphatase were significant prognostic factors in univariate analyses, these factors lost their significance in multivariate analyses. The median survival for patients without any risk factors was 12 months, compared to only 4 months in patients with WHO 2 plus elevated LDH and extensive disease. The performance status, extent of disease, LDH and the addition of paclitaxel to cisplatin are independent prognostic factors in patients with advanced oesophageal cancer, who are treated with cisplatin-based combination chemotherapy.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - mortality</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - therapeutic use</subject><subject>Clinical</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Esophageal Neoplasms - drug therapy</subject><subject>Esophageal Neoplasms - mortality</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Multivariate Analysis</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc-L1DAUx4Mo7rh69ShBcG-dzY-2SS_CsrgqLOhBzyFNX6cpnaQm6che_cvNOMVRwRwS8t7n-80LX4ReUrKlhMvrOG7b0WzrmlBel4_QhlacFVQy8RhtCCGiIA0jF-hZjGO-NkSKp-iClnUpsmCDfnwOfud8TNbgXpvkQ8S9Dzgu4WAPesLW4VknCy5F_N2mAevuoJ2BDnuIfh70DjJljqWAUwCdcusXaGycpyx1RatjLhq_b63LBe-wGWDv0wBBzw_P0ZNeTxFerOcl-nr37svth-L-0_uPtzf3hSklTwVwYXjTgGxAEOiailFiZN22WrS0F40sQUiogDHaVY057rQrhdSk01nX8kv09uQ7L-0eOpO_FPSk5mD3Ojwor636u-PsoHb-oBgXtaxoNrhaDYL_tkBMam-jgWnSDvwSlaAlo3VdZfD1P-Dol-Dy5xRjTV6k4RnaniATfIwB-t-TUKKO2ao4qpytWrPNgld_zn_G1zAz8GYFdDR66kMOxcYzV3HOa3k0uj5xMbfcDsJ5vP88_RPcscFn</recordid><startdate>20031201</startdate><enddate>20031201</enddate><creator>Polee, M B</creator><creator>Hop, W C J</creator><creator>Kok, T C</creator><creator>Eskens, F A L M</creator><creator>van der Burg, M E L</creator><creator>Splinter, T A W</creator><creator>Siersema, P D</creator><creator>Tilanus, H W</creator><creator>Stoter, G</creator><creator>van der Gaast, A</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20031201</creationdate><title>Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy</title><author>Polee, M B ; Hop, W C J ; Kok, T C ; Eskens, F A L M ; van der Burg, M E L ; Splinter, T A W ; Siersema, P D ; Tilanus, H W ; Stoter, G ; van der Gaast, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-e37c399e89e70ed95210c86bba7b1f7984e78e5e221d59c21d51d478a0da399b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - mortality</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - therapeutic use</topic><topic>Clinical</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Esophageal Neoplasms - drug therapy</topic><topic>Esophageal Neoplasms - mortality</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Multivariate Analysis</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Polee, M B</creatorcontrib><creatorcontrib>Hop, W C J</creatorcontrib><creatorcontrib>Kok, T C</creatorcontrib><creatorcontrib>Eskens, F A L M</creatorcontrib><creatorcontrib>van der Burg, M E L</creatorcontrib><creatorcontrib>Splinter, T A W</creatorcontrib><creatorcontrib>Siersema, P D</creatorcontrib><creatorcontrib>Tilanus, H W</creatorcontrib><creatorcontrib>Stoter, G</creatorcontrib><creatorcontrib>van der Gaast, A</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Polee, M B</au><au>Hop, W C J</au><au>Kok, T C</au><au>Eskens, F A L M</au><au>van der Burg, M E L</au><au>Splinter, T A W</au><au>Siersema, P D</au><au>Tilanus, H W</au><au>Stoter, G</au><au>van der Gaast, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2003-12-01</date><risdate>2003</risdate><volume>89</volume><issue>11</issue><spage>2045</spage><epage>2050</epage><pages>2045-2050</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>The objective of this study was to identify prognostic factors for survival in patients with advanced oesophageal cancer, who are treated with cisplatin-based combination chemotherapy. We analysed the baseline characteristics of 350 patients who were treated in six consecutive prospective trials with one of the following regimens: cisplatin/etoposide, cisplatin/etoposide/5-fluorouracil, cisplatin/paclitaxel (weekly) and cisplatin/paclitaxel (biweekly). Predictive factors in univariate analyses were further evaluated using multivariate analysis (Cox regression). The median survival of all patients was 9 months. The 1, 2 and 5-year survival rates were 33, 12 and 4%, respectively. The main prognostic factors were found to be WHO performance status (0 or 1
vs
2), lactate dehydrogenase (normal
vs
elevated), extent of disease (limited disease defined as locoregional irresectable disease or lymph node metastases confined to either the supraclavicular or celiac region
vs
extensively disseminated disease) in addition to the type of treatment (weekly or biweekly cisplatin/paclitaxel regimen
vs
4-weekly cisplatin/etoposide with or without 5-fluorouracil). Although weight loss, liver metastases and alkaline phosphatase were significant prognostic factors in univariate analyses, these factors lost their significance in multivariate analyses. The median survival for patients without any risk factors was 12 months, compared to only 4 months in patients with WHO 2 plus elevated LDH and extensive disease. The performance status, extent of disease, LDH and the addition of paclitaxel to cisplatin are independent prognostic factors in patients with advanced oesophageal cancer, who are treated with cisplatin-based combination chemotherapy.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>14647136</pmid><doi>10.1038/sj.bjc.6601364</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2003-12, Vol.89 (11), p.2045-2050 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2376851 |
| source | MEDLINE; SpringerLink Journals; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - mortality Cisplatin - administration & dosage Cisplatin - therapeutic use Clinical Drug Resistance Epidemiology Esophageal Neoplasms - drug therapy Esophageal Neoplasms - mortality Female Humans Male Medical sciences Middle Aged Molecular Medicine Multivariate Analysis Oncology Prognosis Tumors |
| title | Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T13%3A42%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20factors%20for%20survival%20in%20patients%20with%20advanced%20oesophageal%20cancer%20treated%20with%20cisplatin-based%20combination%20chemotherapy&rft.jtitle=British%20journal%20of%20cancer&rft.au=Polee,%20M%20B&rft.date=2003-12-01&rft.volume=89&rft.issue=11&rft.spage=2045&rft.epage=2050&rft.pages=2045-2050&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6601364&rft_dat=%3Cproquest_pubme%3E71421665%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229999093&rft_id=info:pmid/14647136&rfr_iscdi=true |